Patents Assigned to Genentech, Inc.
  • Patent number: 11939396
    Abstract: The invention provides compositions including anti-tryptase antibodies and pharmaceutical compositions thereof, as well as methods of using the same.
    Type: Grant
    Filed: June 30, 2020
    Date of Patent: March 26, 2024
    Assignee: Genentech, Inc.
    Inventors: Xiaocheng Chen, Mark Dennis, Janet Jackman, James T. Koerber, Mason Lu, Henry R. Maun, Kathila Rajapaksa, Saroja Ramanujan, Tracy Staton, Lawren Wu, Tangsheng Yi
  • Publication number: 20240091100
    Abstract: The needless vial assemblies described herein allow for the access to the contents of a vial, such as a medication, using a syringe without a needle. In some designs, the vial includes a vial neck, which is itself a syringe interface. The vial assemblies also include a cap with a plug, which can be used to seal the vial assembly. The present disclosure further provides methods of filling a vial assembly and methods of filling a syringe using the vial assemblies described herein.
    Type: Application
    Filed: November 15, 2023
    Publication date: March 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Geoffrey WISE, Ajay DESHMUKH, Lionel VEDRINE
  • Publication number: 20240093143
    Abstract: Cell culture media, such as chemically defined cell culture media, are provided, as are methods of using the media for cell growth (i.e., cell culture) and polypeptide (e.g., antibody) production. Compositions comprising polypeptides produced by the methods are also provided.
    Type: Application
    Filed: October 30, 2023
    Publication date: March 21, 2024
    Applicant: GENENTECH, INC.
    Inventors: Natarajan Vijayasankaran, Steven J. Meier, Melissa S. Mun, Sharat Varma, Yi Yang, Boyan Zhang, Silvana R. Arevalo, Martin Gawlitzek, Veronica Carvalhal
  • Publication number: 20240091248
    Abstract: Provided herein are methods for treating acute myeloid leukemia (AML) in a patient with cytopenia when on a combination therapy of venetoclax and azacitidine. Also provided herein are methods of managing a cytopenia in such patient.
    Type: Application
    Filed: November 3, 2023
    Publication date: March 21, 2024
    Applicants: GENENTECH, INC., ABBVIE INC.
    Inventors: Ahmed Hamed SALEM, Jalaja POTLURI, Jiuhong ZHA, Mehrdad MOBASHER, Wan-Jen HONG
  • Patent number: 11932675
    Abstract: The present invention relates to fusion proteins comprising variant IL-15 proteins, fusion proteins comprising variant anti-PD-1 antigen binding domains, and fusion proteins comprising variant IL-15 proteins and variant anti-PD-1 antigen binding domains. The present invention also relates to nucleic acid molecules, expression vectors, host cells and methods for making such fusion proteins and the use of such fusion proteins in the treatment of cancer.
    Type: Grant
    Filed: October 9, 2020
    Date of Patent: March 19, 2024
    Assignees: GENENTECH, INC., XENCOR, INC.
    Inventors: John Desjarlais, Matthew Bernett, Michael Hedvat, Rajat Varma, Suzanne Schubbert, Christine Bonzon, Rumana Rashid, Juan Diaz, Patrick Holder, Christine Huang
  • Publication number: 20240084391
    Abstract: This application discloses methods of designing a treatment protocol for a human patient with ovarian cancer, as well as methods of treatment of ovarian cancer. This application also includes methods of characterizing an ovarian cancer in a human patient by the type of tumor.
    Type: Application
    Filed: August 25, 2023
    Publication date: March 14, 2024
    Applicant: Genentech, Inc.
    Inventors: Milena Rosa Hornburg, Yulei Wang
  • Publication number: 20240084240
    Abstract: A method, system, and non-transitory computer readable medium for predicting cell viability of a cell culture in a bioreactor during a biomolecule manufacturing process are disclosed. In various embodiments, at least three manufacturing process parameters related to the process for manufacturing molecules are input into a machine learning model that is trained to predict cell viabilities. The trained machine learning model may then analyze the at least three manufacturing process parameters to generate an indicator of cell viability of the cell culture.
    Type: Application
    Filed: September 8, 2023
    Publication date: March 14, 2024
    Applicant: GENENTECH, INC.
    Inventors: Arthi NARAYANAN, Aditya Avdhut WALVEKAR, Georo L. ZHOU, Nicholas RUMMEL, Zheng LI, Steven J. MEIER
  • Publication number: 20240084241
    Abstract: A method, system, and non-transitory computer readable medium for predicting a glycan distribution of one or more glycans attached to molecules during a biomolecules manufacturing process are disclosed. In various embodiments, at least three manufacturing process parameters related to the process for manufacturing the molecules are input into a probabilistic graphical model that is trained to predict glycan distribution. The trained probabilistic graphical model may then analyze the at least three manufacturing process parameters to predict the distribution of the glycans that are attached to the molecules.
    Type: Application
    Filed: September 8, 2023
    Publication date: March 14, 2024
    Applicant: GENENTECH, INC.
    Inventors: Arthi NARAYANAN, Aditya Avdhut WALVEKAR, Georo L. ZHOU, Nicholas RUMMEL, Zheng LI, Steven J. MEIER
  • Publication number: 20240083980
    Abstract: The present invention relates to the field of protein purification. In particular, the invention concerns methods for increasing the filtration capacity of virus filters, by combined use of endotoxin removal and cation-exchange media in the prefiltration process.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 14, 2024
    Applicant: Genentech, Inc.
    Inventor: Amit MEHTA
  • Publication number: 20240084042
    Abstract: The invention provides anti-KLK7 antibodies, anti-KLK5 antibodies, anti-KLK5/KLK7 multispecific antibodies, and methods of using the same.
    Type: Application
    Filed: September 11, 2023
    Publication date: March 14, 2024
    Applicant: Genentech, Inc.
    Inventors: James Thomas Koerber, Wyne Pun Lee, Tangsheng Yi, Juan Zhang, Cary Dean Austin, Cecilia Pui Chi Chiu, Joseph Edward Chavarria-Smith, Jawahar Sudhamsu
  • Publication number: 20240087689
    Abstract: The present disclosure relates to techniques for abstraction of unstructured clinical trial health data. Particularly, aspects are directed to obtaining, by a data transformation system, an unstructured document that includes various types of content for a given event. The data transformation system converts the unstructured document from an original format into a standardized format. The data transformation system processes the unstructured document in the standardized format to identify template-mapped content data and processes the template-mapped content data to identify high-interest content data. The data transformation system generates a dictionary data structure comprising key-value pairs for each of the template-mapped content data and the high-interest content data. The data transformation system generates a structured document based on the dictionary data structure for each of the template-mapped content data and the high-interest content data.
    Type: Application
    Filed: November 21, 2023
    Publication date: March 14, 2024
    Applicant: GENENTECH, INC.
    Inventors: Lukas Robert Corey, Jennifer Renee Crawford, Connor Patrick Douglas, Benjamin Pamandanan Femandez
  • Publication number: 20240085404
    Abstract: The present disclosure relates to methods and compositions useful for measuring the transcytosis or recycling of a molecule. In particular, the present disclosure relates to in vitro receptor-dependent transcytosis or recycling assays for evaluating the clearance rates of therapeutic antibody molecules and Fc-fusion proteins in humans and animals.
    Type: Application
    Filed: October 13, 2023
    Publication date: March 14, 2024
    Applicant: Genentech, Inc.
    Inventors: Chang LIU, John Hok Nin LOWE, Shan CHUNG
  • Patent number: 11925624
    Abstract: The present disclosure relates to methods of administering Compound I for treating fibrotic disorders, inflammatory disorders or autoimmune disorders.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: March 12, 2024
    Assignee: GENENTECH, INC.
    Inventors: Lin Pan, Dorothy Sze-Wing Cheung, Jeffrey Mark Harris, Indiana Strombom
  • Patent number: 11926674
    Abstract: The invention provides anti-Jagged2 antibodies and methods of using the same.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: March 12, 2024
    Assignee: Genentech, Inc.
    Inventors: Yvonne Chinn, Julie Q. Hang, Christian W. Siebel, Yan Wu, Daniel Lafkas
  • Publication number: 20240076358
    Abstract: Methods of treating Alzheimer's Disease (AD) in patients suffering from early AD, including amyloid positive patients, ApoE4 positive patients, and patients suffering from prodromal or mild AD are provided.
    Type: Application
    Filed: February 6, 2023
    Publication date: March 7, 2024
    Applicant: GENENTECH, INC.
    Inventors: Jillian Smith, Janice Smith, Geoff Kerchner
  • Publication number: 20240076388
    Abstract: The invention provides FGFR1 agonists, including agonistic anti-FGFR1 antibodies, and methods of using the same.
    Type: Application
    Filed: April 3, 2023
    Publication date: March 7, 2024
    Applicant: GENENTECH, INC.
    Inventors: Junichiro Sonoda, Yan Wu
  • Patent number: 11918561
    Abstract: Provided herein are combination therapies comprising GDC-9545 and a CDK4/6 inhibitor for treating locally advanced breast cancer or metastatic breast cancer.
    Type: Grant
    Filed: May 10, 2021
    Date of Patent: March 5, 2024
    Assignee: Genentech, Inc.
    Inventors: Jennifer O'Hara Lauchle, Sandra Milan, Melanie Carol Smitt, Marjorie C. Green
  • Patent number: 11919948
    Abstract: The invention provides isoform-selective anti-TGF? antibodies and methods of using the same. In particular, isoform-selective anti-TGF?2, anti-TGF?3, and anti-TGF?2/3 monoclonal antibodies are provided, e.g., for the treatment of fibrosis and other TGF?-related disorders.
    Type: Grant
    Filed: March 18, 2021
    Date of Patent: March 5, 2024
    Assignee: GENENTECH, INC.
    Inventors: Wei-Ching Liang, Joseph R. Arron, Daryle Depianto, Wendy Green Halpern, WeiYu Lin, Patrick J. Lupardus, Thirumalai Rajan Ramalingam, Dhaya Seshasayee, Tianhe Sun, Tulika Tyagi, Jia Wu, Yan Wu, Jian Ping Yin
  • Publication number: 20240067707
    Abstract: The invention provides anti-Tau antibodies and methods of using the same.
    Type: Application
    Filed: December 13, 2022
    Publication date: February 29, 2024
    Applicants: Genentech, Inc., AC Immune SA
    Inventors: Oskar Adolfsson, Gai Ayalon, Isidro Hotzel, Danielle Marie Di Cara
  • Publication number: 20240067709
    Abstract: Anti-K63-linked polyubiquitin monoclonal antibodies, and methods for using the antibodies, are provided.
    Type: Application
    Filed: July 18, 2023
    Publication date: February 29, 2024
    Applicant: Genentech, Inc.
    Inventors: Robert F. Kelley, Marissa L. Matsumoto